Skip to main content
SpringerLink
Log in

Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects

  • Introduction
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  • Fenton WS, Stover EL, Insel TR (2003) Breaking the log-jam in treatment development for cognition in schizophrenia. Psychopharmacology 169:365–366

    Article  CAS  PubMed  Google Scholar 

  • Hyman SE, Fenton WS (2003) What are the right targets for psychopharmacology? Science 299:350–351

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry-0804, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0804, USA

    Mark A. Geyer

  2. Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, NC5 914, Dallas, TX, 75390-4924, USA

    Carol A. Tamminga

Authors
  1. Mark A. Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol A. Tamminga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark A. Geyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geyer, M.A., Tamminga, C.A. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology 174, 1–2 (2004). https://doi.org/10.1007/s00213-004-1846-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-004-1846-2

Keywords

Search

Navigation